stockrowRelay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- 0.00%
- Free cash flow
- +2.13%
Quarter to June 2026, against a year earlier
Follow RLAY
Alert me
Relay Therapeutics, Inc. (RLAY) Return on assets
Relay Therapeutics, Inc.'s return on assets over the twelve months to 30 June 2026 was −33.7%, up 3.3 percentage points from fiscal 2025 (−37.1%). Over the past ten years it has ranged from −40.3% (fiscal 2021) to −18.3% (fiscal 2019); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −37.1% | 2.33 |
| FY2024 | −39.4% | (4.19) |
| FY2023 | −35.2% | (7.63) |
| FY2022 | −27.6% | 12.69 |
| FY2021 | −40.3% | (1.65) |
| FY2020 | −38.6% | (20.28) |
| FY2019 | −18.3% | 4.42 |
| FY2018 | −22.7% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 23.2% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| ABCL AbCellera Biologics Inc. compare | −12.2% |
| TNGX Tango Therapeutics, Inc. compare | −18.9% |
| IOVA Iovance Biotherapeutics, Inc. compare | −23.3% |
| RLAY Relay Therapeutics, Inc. | −33.7% |
| IRON Disc Medicine, Inc. compare | −35.1% |
| EWTX Edgewise Therapeutics, Inc. compare | −36.1% |
| XENE Xenon Pharmaceuticals Inc. compare | −41.5% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on RLAY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement